Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative

N. Groot, N. de Graeff, SD. Marks, P. Brogan, T. Avcin, B. Bader-Meunier, P. Dolezalova, BM. Feldman, I. Kone-Paut, P. Lahdenne, L. McCann, S. Özen, CA. Pilkington, A. Ravelli, AV. Royen-Kerkhof, Y. Uziel, BJ. Vastert, NM. Wulffraat, MW....

. 2017 ; 76 (12) : 1965-1973. [pub] 20170906

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18016366

Lupus nephritis (LN) occurs in 50%-60% of patients with childhood-onset systemic lupus erythematosus (cSLE), leading to significant morbidity. Timely recognition of renal involvement and appropriate treatment are essential to prevent renal damage. The Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative aimed to generate diagnostic and management regimens for children and adolescents with rheumatic diseases including cSLE. Here, we provide evidence-based recommendations for diagnosis and treatment of childhood LN. Recommendations were developed using the European League Against Rheumatism standard operating procedures. A European-wide expert committee including paediatric nephrology representation formulated recommendations using a nominal group technique. Six recommendations regarding diagnosis and 20 recommendations covering treatment choices and goals were accepted, including each class of LN, described in the International Society of Nephrology/Renal Pathology Society 2003 classification system. Treatment goal should be complete renal response. Treatment of class I LN should mainly be guided by other symptoms. Class II LN should be treated initially with low-dose prednisone, only adding a disease-modifying antirheumatic drug after 3 months of persistent proteinuria or prednisone dependency. Induction treatment of class III/IV LN should be mycophenolate mofetil (MMF) or intravenous cyclophosphamide combined with corticosteroids; maintenance treatment should be MMF or azathioprine for at least 3 years. In pure class V LN, MMF with low-dose prednisone can be used as induction and MMF as maintenance treatment. The SHARE recommendations for diagnosis and treatment of LN have been generated to support uniform and high-quality care for all children with SLE.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016366
003      
CZ-PrNML
005      
20180515103848.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/annrheumdis-2017-211898 $2 doi
035    __
$a (PubMed)28877866
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Groot, Noortje $u Wilhelmina Children's Hospital, Utrecht, The Netherlands. Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.
245    10
$a European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative / $c N. Groot, N. de Graeff, SD. Marks, P. Brogan, T. Avcin, B. Bader-Meunier, P. Dolezalova, BM. Feldman, I. Kone-Paut, P. Lahdenne, L. McCann, S. Özen, CA. Pilkington, A. Ravelli, AV. Royen-Kerkhof, Y. Uziel, BJ. Vastert, NM. Wulffraat, MW. Beresford, S. Kamphuis,
520    9_
$a Lupus nephritis (LN) occurs in 50%-60% of patients with childhood-onset systemic lupus erythematosus (cSLE), leading to significant morbidity. Timely recognition of renal involvement and appropriate treatment are essential to prevent renal damage. The Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative aimed to generate diagnostic and management regimens for children and adolescents with rheumatic diseases including cSLE. Here, we provide evidence-based recommendations for diagnosis and treatment of childhood LN. Recommendations were developed using the European League Against Rheumatism standard operating procedures. A European-wide expert committee including paediatric nephrology representation formulated recommendations using a nominal group technique. Six recommendations regarding diagnosis and 20 recommendations covering treatment choices and goals were accepted, including each class of LN, described in the International Society of Nephrology/Renal Pathology Society 2003 classification system. Treatment goal should be complete renal response. Treatment of class I LN should mainly be guided by other symptoms. Class II LN should be treated initially with low-dose prednisone, only adding a disease-modifying antirheumatic drug after 3 months of persistent proteinuria or prednisone dependency. Induction treatment of class III/IV LN should be mycophenolate mofetil (MMF) or intravenous cyclophosphamide combined with corticosteroids; maintenance treatment should be MMF or azathioprine for at least 3 years. In pure class V LN, MMF with low-dose prednisone can be used as induction and MMF as maintenance treatment. The SHARE recommendations for diagnosis and treatment of LN have been generated to support uniform and high-quality care for all children with SLE.
650    _2
$a hormony kůry nadledvin $x terapeutické užití $7 D000305
650    _2
$a věk při počátku nemoci $7 D017668
650    _2
$a antirevmatika $x terapeutické užití $7 D018501
650    _2
$a azathioprin $x terapeutické užití $7 D001379
650    _2
$a dítě $7 D002648
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a management nemoci $7 D019468
650    _2
$a Evropa $7 D005060
650    _2
$a medicína založená na důkazech $x normy $7 D019317
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a nefritida při lupus erythematodes $x diagnóza $x farmakoterapie $7 D008181
650    _2
$a kyselina mykofenolová $x terapeutické užití $7 D009173
650    12
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a indukce remise $x metody $7 D012074
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a de Graeff, Nienke $u Wilhelmina Children's Hospital, Utrecht, The Netherlands.
700    1_
$a Marks, Stephen D $u Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
700    1_
$a Brogan, Paul $u Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
700    1_
$a Avcin, Tadej $u University Children's Hospital Ljubljana, Ljubljana, Slovenia.
700    1_
$a Bader-Meunier, Brigitte $u Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
700    1_
$a Dolezalova, Pavla $u 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Feldman, Brian M $u Division of Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Kone-Paut, Isabelle $u Bicêtre Hospital, Paris, APHP, University of Paris Sud, Paris, France.
700    1_
$a Lahdenne, Pekka $u Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
700    1_
$a McCann, Liza $u Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
700    1_
$a Özen, Seza $u Department of Pediatrics, Hacettepe University, Ankara, Turkey.
700    1_
$a Pilkington, Clarissa A $u Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
700    1_
$a Ravelli, Angelo $u Università degli Studi di Genova and Istituto Giannina Gaslini, Genoa, Italy.
700    1_
$a Royen-Kerkhof, Annet van $u Wilhelmina Children's Hospital, Utrecht, The Netherlands.
700    1_
$a Uziel, Yosef $u Meir Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
700    1_
$a Vastert, Bas J $u Wilhelmina Children's Hospital, Utrecht, The Netherlands.
700    1_
$a Wulffraat, Nico M $u Wilhelmina Children's Hospital, Utrecht, The Netherlands.
700    1_
$a Beresford, Michael W $u Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
700    1_
$a Kamphuis, Sylvia $u Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 76, č. 12 (2017), s. 1965-1973
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28877866 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515104021 $b ABA008
999    __
$a ok $b bmc $g 1299990 $s 1013206
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 76 $c 12 $d 1965-1973 $e 20170906 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options